Drug development: RGN259 Phase II trial underway

Safety and Efficacy of Thymosin Beta 4 Ophthalmic Solution in Patients With Dry Eye (clinicaltrials.gov page)

Newsblurb from August 26

RegeneRx Biopharmaceuticals reported enrolling all 72 patients in its phase 2 trial of its RGN-259 treatment for dry-eye syndrome.

Patients will receive RGN-259 or a placebo twice daily until Sept. 23. The Rockville biotech expects preliminary data available in October.

In animal models, RGN-259 worked better than Restasis — the only FDA-approved drug for dry-eye syndrome — for certain conditions, according to a RegeneRx statement.